{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-053557","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.183353+00:00","generated_at":"2026-06-28T15:09:11.497011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO Q3 net loss $58.4M; AbbVie collaboration for RGX-314 with $370M upfront","bullets":["AbbVie collaboration: $370M upfront, up to $1.38B milestones, 50/50 U.S. profit share.","Q3 revenue $30.8M (prior year $98.9M included $80M milestone); net loss $58.4M vs prior year net income $8.8M.","Cash $533.5M; expects to fund operations into H2 2023, excluding AbbVie deal proceeds.","RGX-314 Phase II: stable visual acuity and reduced anti-VEGF burden in wet AMD; 33% of DR patients improved ≥2 steps.","IND for RGX-202 for Duchenne muscular dystrophy on track for end of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-053557","json":"https://secwatch.observer/filing/0001564590-21-053557.json","markdown":"https://secwatch.observer/filing/0001564590-21-053557.md","text":"https://secwatch.observer/filing/0001564590-21-053557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/0001564590-21-053557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/rgnx-8k_20211102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:09:11.497011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}